Date:3/19/2013

nd other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported or see the advantages of using the Company's PCT platform in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond April 2013. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond April 2013 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

           For more information about PBI and this press release, please click on the following link:                                   &
'/>"/>

SOURCE Pressure BioSciences, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Microfabrication breakthrough could set piezoelectric material applications in motion
2. Quantum computing has applications in magnetic imaging, say Pitt researchers
3. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
4. Manipulating way bacteria talk could have practical applications, Texas A&M profs say
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
7. TOKU-E Announces Safer and Faster Dissolving, Dust-Free Grade Sodium Dodecyl Sulfate (SDS) for Electrophoresis and Manufacturing Applications
8. Global Markets for Enzymes in Industrial Applications
9. Global Markets for Enzymes in Industrial Applications -- Focus on Europe
10. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
11. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union